A trial of OPC-167832 in combination with Delamanid in drug susceptible tuberculosis patients

Next Previous
Trial Profile

A trial of OPC-167832 in combination with Delamanid in drug susceptible tuberculosis patients

Planning
Phase of Trial: Phase I

Latest Information Update: 01 Feb 2018

At a glance

  • Drugs Delamanid (Primary) ; OPC-167832 (Primary)
  • Indications Tuberculosis
  • Focus Adverse reactions

    • Most Recent Events

    • 01 Feb 2018 New trial record
    • 29 Jan 2018 According to an Otsuka media release, the company received a grant for up to US $10 million from the Bill & Melinda Gates Foundation to advance clinical development of OPC-167832 in combination with delamanid to treat tuberculosis (TB).
    • 29 Jan 2018 According to an Otsuka media release, this trial is scheduled to begin in the fourth quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top